Straits Times Index
3,257.18 -5.36 (-0.16%) S&P 500
4,046.00 +18.19 (+0.45%) Dow
32,761.19 +43.59 (+0.13%) Nasdaq
12,009.63 +83.39 (+0.70%) Bitcoin USD
28,361.88 -110.34 (-0.39%) CMC Crypto 200
616.84 -2.40 (-0.39%)
LLY Sep 2023 490.000 call
| Previous close | 1.0700 |
| Open | 1.0700 |
| Bid | 0.4100 |
| Ask | 1.1600 |
| Strike | 490.00 |
| Expiry date | 2023-09-15 |
| Day's range | 1.0700 - 1.0700 |
| Contract range | N/A |
| Volume | |
| Open interest | 59 |
- Motley Fool
3 Stocks That Could Benefit From the Ozempic Craze
Ozempic is a drug that has been soaring in popularity over the past year. Three companies that can benefit from the excitement around this weight-loss treatments are Novo Nordisk (NYSE: NVO), Eli Lilly (NYSE: LLY), and WW International (NASDAQ: WW). The biggest benefactor of Ozempic's popularity is likely to be the company that makes the treatment itself: Novo Nordisk.
- Motley Fool
3 Dividend Stocks That Have Been Paying Investors Since the 1800s
Three businesses that have not only been around for more than a century but have also been paying dividends going back to the 1800s are Eli Lilly (NYSE: LLY), ExxonMobil (NYSE: XOM), and the Toronto-Dominion Bank (NYSE: TD). Healthcare giant Eli Lilly has been paying a dividend since 1885.
- Reuters
Boehringer's profit up as Jardiance gains offset higher costs
FRANKFURT (Reuters) -German unlisted drugmaker Boehringer Ingelheim said on Wednesday its operating income rose 1.4% in 2022, as more prescriptions of diabetes drug Jardiance trumped higher energy and development costs. Family-owned Boehringer said in its annual report that full-year operating income came in at 4.77 billion euros ($5.17 billion), up from 4.71 billion a year earlier. The Jardiance group of products, managed in a partnership with Eli Lilly, made 5.8 billion euros in sales, a currency-adjusted surge of 39.1%.
